Given the close relationship between lipid metabolic disorder, inflammation, oxidative stress and ERS in driving NAFLD progression, investigating EPT’s regulatory effects on COX2 and ERS might offer new therapeutic insights. This evidence concerns the gene PTGS2 and metabolic dysfunction-associated steatotic liver disease.